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In relapse-onset multiple sclerosis (MS), tissue abnormality – as assessed with 
magnetisation transfer ratio (MTR) imaging - is greater in the outer cortical and inner 
periventricular layers. The cause of this remains unknown but meningeal inflammation has 
been implicated, particularly lymphoid follicles, which are seen in secondary progressive 
(SP) but not primary progressive (PP) MS. Cortical and periventricular MTR gradients might 
therefore differ in PPMS and SPMS if these follicles are responsible. 
 
Objective 
We assessed cortical and periventricular MTR gradients in PPMS; and compared gradients 
between people with PPMS and SPMS. 
 
Methods 
Using an optimised processing pipeline, periventricular normal-appearing white matter and 
cortical grey-matter MTR gradients were compared between 51 healthy controls and 63 
people with progressive MS (28 PPMS, 35 SPMS). 
 
Results 
The periventricular gradient was significantly shallower in healthy controls (0.122 
percentage units (pu)/band) compared to PPMS (0.952 pu/band, p<0.0001) and SPMS 
(1.360 pu/band, p<0.0001). The cortical gradient was also significantly shallower in healthy 
controls (-2.860 pu/band) compared to PPMS (-3.214 pu/band, p=0.038) and SPMS (-3.328 
pu/band, p=0.016)).  
 
Conclusion 
Abnormal periventricular and cortical MTR gradients occur in both PPMS and SPMS 
suggesting comparable underlying pathological processes.  
INTRODUCTION 
There is ongoing debate as to whether or not primary progressive (PP) and secondary 
progressive (SP) multiple sclerosis (MS) are essentially the same disease, barring the 
preceding relapsing-remitting (RR) phase: the age at onset and rate of progression are 
similar1 and lesion morphology in relapse-onset and PPMS are identical,2 but differences 
have been observed in both MRI and histopathological studies.3, 4 Post-mortem studies have 
recently revealed meningeal inflammation in all types of MS,5-7 although the most 
structured form - lymphoid follicle-like aggregates - have only been observed in SPMS, not 
in PPMS.6 The presence of these follicles - noted in about 40% of people with SPMS - is 
associated with more rapid clinical progression, and histopathologically with subpial 
demyelination and a gradient of cortical axonal loss.8 This raises seemingly conflicting 
possibilities that either lymphoid follicles are themselves not relevant to progression, or that 
the mechanisms leading to progression differ significantly between PPMS and SPMS. 
 
Consistent with these histopathological findings, tissue abnormality, as assessed by 
magnetisation transfer ratio (MTR) in vivo, increases towards the cortical surfaces in all 
clinical stages of relapse-onset MS.9 We have recently shown similar gradients in MTR 
abnormality around the ventricles in relapse-onset MS.10 Both cortical and periventricular 
gradients are evident soon after a clinically-isolated syndrome11, 12 and are more marked in 
SPMS compared to RRMS.9, 10 The processes underlying abnormal cortical and 
periventricular MTR gradients remain unknown, but one possibility is that they are both 
linked with meningeal inflammation, perhaps through a CSF-mediated factor.8 We 
previously reported the absence of a statistically significant cortical MTR gradient in PPMS9 
but did not investigate  periventricular gradients. If a common factor links cortical and 
periventricular MTR gradients, we would expect the latter to also be absent in PPMS. 
 
Using our recently optimised pipeline for MTR gradient analysis13 we aimed to: (i) confirm 
the absence of a gradient of cortical MTR abnormality in PPMS; (ii) determine if an 
abnormal periventricular MTR gradient is seen in PPMS; (iii) compare gradients and their 
evolution between people with PPMS and SPMS; and (iv) explore correlations with 
disability. As the processing pipeline has been optimised since previous publications,9, 10 we 
also reprocessed data from people with RRMS and present them as an online supplement 
(Supplementary Tables 1-2). 
  
MATERIALS AND METHODS 
Subjects 
From an observational cohort9 we analysed data from healthy controls and people with 
PPMS, SPMS or RRMS (as defined by the Lublin-Reingold criteria14) that had undergone MRI 
scanning with a protocol including the acquisition of volumetric T1-weighted images and 
MTR data. Some had repeat imaging performed 1-4 years later. All people in the MS groups 
additionally required an Expanded Disability Status Scale (EDSS15) score at baseline. The 
study was approved by our local institutional ethics committee and written informed 
consent was provided by each participant. 
 
MRI 
Imaging was performed on a 3T Philips Achieva system (Philips Healthcare, Best, The 
Netherlands), and included: (i) Dual-echo proton density / T2 weighted scans (1x1x3 mm3, 
TR = 3500 ms, TE = 19/85 ms) for lesion identification; (ii) T1-weighted scans (3D inversion-
prepared (T1=824 ms) fast field echo sequence (TR/TE = 6.9/3.1 ms, flip angle = 8°) for 
volumetric measures and segmentation; and (iii) MTR data using a 3D-slab-selective fast 
field echo sequence with two echoes (TR = 6.4 ms, TE1/TE2 = 2.7/4.3 ms, flip angle = 9° with 
and without sinc-Gaussian shaped MT pulses of nominal flip angle 360°, offset frequency 1 
kHz, duration 16 ms). All images were acquired sagittally with a field-of-view of 
256x256x180mm3 across the whole brain. 
 
Image analysis 
White matter (WM) lesions were outlined on PD/T2-weighted images using the semi-
automated tool 3D-slicer16 and checked by DTC. The resultant lesion masks were affine co-
registered to the T1-weighted images via pseudo-T1 images (as previously described17) and 
transformed to T1-space using nearest-neighbour interpolation to enable lesion-filling of the 
T1-weighted images.18 The MTon and MToff images were then registered to the T1-
weighted volume using NiftyReg,19 and MTR maps (in percentage units (pu)), were 
calculated as follows: (((MToff – MTon) / MToff) x100). T1-weighted volumes were 
segmented into WM, grey matter (GM) and cerebrospinal fluid (CSF) using the geodesic 
information flows (GIF)20 algorithm. Lesions (plus a 2mm perilesional rim21) were subtracted 
from each participant’s WM mask, generating a normal-appearing (NA) WM mask. The 
NAWM and cortical GM (CGM) volumes were used as covariates in the periventricular and 
cortical models respectively. Brain parenchymal fraction (BPF) was used as an alternative 
covariate in both periventricular and cortical gradient models in a sensitivity analysis to 
mirror a previous paper.13 It was calculated as follows: (GM volume + WM volume) / (GM 
volume + WM volume + CSF volume). 
The NAWM mask was intersected with the MTR map, and segmented into 10 concentric 
bands using the normalised distance map derived from the normal to the Laplace equation 
isolines.13 This approach generates bands of varying thickness, but accounts for the 
differences in brain thickness within different brain regions plus the effects of atrophy: the 
relative position of a given band to the surface of the brain should therefore be maintained. 
Consistent with previous work using 3D MTR data, the innermost (periventricular) and 
outermost (pericortical) bands were excluded to mitigate partial volume effects.10 From the 
remaining 8 bands the periventricular NAWM gradient was calculated as follows: ((mean 
NAWM MTR band 3 – mean NAWM MTR band 1) / 2). Consistent with previous work, the 
CGM was also segmented into two bands using the Laplace method9 but rather than using 
the absolute outer-band MTR value9 (which will be subject to inter-individual variations in 
whole brain MTR22), the cortical gradient was instead calculated as: ((mean cortical GM MTR 
band 2 (outer) – mean cortical GM MTR band 1 (inner)) / 2). An alternative method for 
calculating the cortical gradient – applying the CGM mask to a 12-ring segmentation, 
removing the outermost band, then calculating the cortical gradient over the 3 outermost 
rings – requires a lower probabilistic segmentation threshold13 to achieve similarly-sized 
rings, so increasing the chances of partial volume with adjacent WM and CSF, affecting 
results, and it also does not account for cortical folding as well as the present method. The 
mean NAWM and cortical GM MTR were also calculated in each participant for use as 
covariates in sensitivity analyses. Finally, to explore whether differences between current 
and previous9 results reflected the greater number of people studied, we restricted the 
groups to the 19 people with PPMS and 35 healthy controls previously examined9 and 
repeated the analyses.  
 
Statistics 
MTR gradient values are presented as mean ± standard error, and all longitudinal 
differences were annualised to circumvent variable interscan intervals. We used general 
linear models to compare baseline gradients between groups and mixed-effects linear 
models to compare the rate of gradient change between disease subtypes. Consistent with 
previous work these models were adjusted for age and sex. Additionally, these models were 
also adjusted for either NAWM volume (periventricular gradient models) or cortical volume 
(cortical gradient models); and then repeated adjusting for brain parenchymal fraction (BPF) 
for comparison to previous work.13  To examine whether differences in gradients might be 
driven by more diffuse MTR changes we performed sensitivity analyses, additionally 
adjusting all periventricular gradient models for mean NAWM MTR, and all cortical gradient 
models for mean CGM MTR.  
Finally, we ran univariate general linear models comparing (i) baseline periventricular 
gradients with baseline cortical gradients; and (iii) baseline gradients with baseline disease 
duration, EDSS score and time from the last relapse. All analyses were performed in R 
(v3.3.1). Results were considered statistically significant at the p < 0.05 level. 
  
RESULTS 
Imaging was performed in 51 healthy controls (12 with follow-up imaging after median 2.1 
(range 1.5 – 2.7) years), 28 people with PPMS (14 with follow-up imaging after median 2.3 
(range 1.2 – 3.5) years) and 35 people with SPMS (15 with follow-up imaging after median 
1.6 (range 1.1 – 2.4) years). The control group were younger than either progressive group 
(Table 1), and the SPMS group had a greater proportion of females than the PPMS and 
control groups (all models were adjusted for age, gender and either NAWM volume or CGM 
volume).  
 
The MTR in each band was greater (less abnormal) in healthy controls compared to those 
with PPMS and SPMS (Figure 1). The NAWM periventricular gradient was significantly 
shallower (less abnormal) in healthy controls (0.122 ± 0.038 pu/band) compared to those 
with both PPMS (0.952 ± 0.185 pu/band, p < 0.0001)  and SPMS (1.360 ± 0.143 pu/band, p < 
0.0001), Table 2, Figure 2A. These differences persisted when the models were additionally 
adjusted for mean NAWM MTR (p = 0.015  and p < 0.0001 respectively) and when the 
models were adjusted for BPF instead of NAWM volume (p < 0.001 and p = 0.003 
respectively). No significant differences in periventricular gradient were found between 
people with PPMS and SPMS (p = 0.444), including after adjustment for mean NAWM MTR 
(p = 0.191) or when covarying for BPF instead of NAWM volume (p = 0.604). The cortical 
gradient was significantly shallower (less abnormal) in healthy controls (-2.860 ± 0.051 
pu/band) compared with both PPMS (-3.214 ± 0.103 pu/band, p = 0.038) and SPMS (-3.328 
± 0.101 pu/band, p = 0.016), Figure 2B. These differences lost significance when the models 
were additionally adjusted for mean cortical GM MTR (p = 0.570 and p = 0.589  
respectively), and when the models covaried for BPF instead of cortical volume (p = 0.575 
and p = 0.530 respectively).  When the MS and healthy control groups were limited to those 
analysed previously9 the results were consistent with those previously seen: a significant 
difference was seen between healthy controls and SPMS (p=0.030) but not PPMS (p = 
0.150). No significant differences in cortical gradient were found between people with 
PPMS and SPMS (p = 0.372), including after adjustment for mean cortical MTR (p = 0.915).  
The baseline demographics and imaging outcomes (including model results) for people with 
RRMS are presented in Supplementary Tables 1 and 2 respectively. 
 
When all people with MS were grouped (RRMS, SPMS, PPMS), the baseline periventricular 
gradient was associated with baseline EDSS score ( 0.100, p=0.011) and disease duration ( 
0.023, p=0.005) but not time from last relapse ( 0.021, p=0.357). These associations did not 
materially change when additionally adjusted for clinical classification (Table 3). The 
baseline cortical gradient was associated with baseline EDSS score ( -0.082, p=0.001) and 
disease duration ( -0.015, p=0.004) but not time from last relapse ( -0.011, p=0.554). 
These associations did not materially change when additionally adjusted for clinical 
classification. Results for each disease subgroup are shown in Table 3.  A significant 
association was found between the periventricular gradient and cortical gradient ( -0.609, 
p<0.0001) which remained unchanged after additionally adjusting for disease group (Table 
3).  
 
In those with radiological follow-up (Tables 1-2), the annualised change in periventricular 
gradient was not significantly different between healthy controls -0.011 ± 0.051 
pu/band/year) and people with either PPMS (0.090 ± 0.040 pu/band/year, p = 0.951) or 
SPMS (0.021 ± 0.030 pu/band/year, p = 0.473). Including change in mean NAWM MTR in the 
model did not materially alter the results (p = 0.882 and p = 0.343, respectively). Similarly, 
no change in the annualised rate of change in cortical gradient was seen between healthy 
controls (0.090 ± 0.146 pu/band/year) and people with either PPMS (-0.018 ± 0.039 
pu/band/year, p = 0.553) or SPMS (0.037 ± 0.009 pu/band/year, p = 0.913). Including change 
in mean cortical GM MTR in the model did not materially alter the results (p = 0.964 and p = 
0.350, respectively).  
  
DISCUSSION 
We identified both periventricular and cortical MTR gradients in PPMS and replicated our 
previous findings of cortical and periventricular gradients in SPMS.9, 10 The cortical and 
periventricular gradients did not differ significantly between the PPMS and SPMS groups. In 
the few subjects with longitudinal imaging, when compared with healthy controls, no 
significant changes in these gradients were observed over a median period of 2 years. When 
all people with MS were combined, significant associations were seen between 
periventricular and cortical gradient severity; and both gradients increased with increasing 
disability and disease duration.  
 
The present results suggest that the processes underlying cortical and periventricular MTR 
gradients may be similar in PPMS and SPMS. The finding of a cortical gradient in PPMS in the 
present study but not our previous work9 appears to reflect the larger cohort (28 versus 19 
with PPMS; 51 versus 35 healthy controls). However, while the optimised processing 
pipeline better accounts for cortical folding, it’s ability to distinguish cortical gradients from 
whole cortical MTR effects is severely limited because cortical gradients are calculated from 
the only 2 cortical bands of MTR, which may explain why all cortical models lost significance 
when additionally covaried for mean CGM MTR.  
 
The pathological substrate and pathogenic processes underlying these MTR gradients 
remain unknown, but MTR reductions are correlated with demyelination in the cortex and 
WM23-25 and additionally axonal loss in WM.25 In the cortex, demyelination and neuronal 
loss appear more extensive in the outer (subpial) layers so both might therefore contribute 
to a gradient in cortical MTR abnormality.5, 6, 8, 26 Both have also been linked with meningeal 
inflammation, particularly follicle-like lymphoid aggregates. The present findings suggest 
these follicles – reported in about 40% of people with SPMS but not in PPMS6 - are not 
necessary for a gradient in cortical MTR abnormality to occur. However, the absence of 
follicles in PPMS at post-mortem may reflect the relatively small number examined6 (n=7) 
and larger histopathological studies are warranted to confirm this. To the best of our 
knowledge no histopathological study has examined periventricular gradients, so it remains 
to be determined if the underlying substrates are similar to those in the cortex. However, 
the present results would be consistent with a common pathological process underlying 
them both.27, 28  
The presence of a significant association between cortical and periventricular gradients in 
the RRMS group (n=56) but not the PPMS (n=28) or SPMS (n=35) groups may also reflect the 
smaller sample sizes, particularly given the significant association seen at the whole-group 
level when additionally covarying for clinical classification.  The apparent absence of a 
change in gradients over time should also be interpreted with caution, given that only a 
small subset of the cohorts had serial MTR studies (12/51 healthy controls, 14/28 with 
PPMS and 15/35 with SPMS), and follow-up was limited to 1.6-2.3 years (Table 1). This and 
previous cross-sectional works have shown a steeper periventricular gradient in SPMS 
compared with RRMS.10 and we found significant associations between disease duration 
and gradient severity (Table 3), collectively suggesting that gradients do worsen over time. 
Associations of cortical and periventricular MTR gradients with disability, as measured by 
EDSS scores, were also modest. Only in SPMS did cortical MTR gradients correlate with EDSS 
scores, though the significant correlations at the whole-group level - even when covarying 
for clinical classification - may suggest that the lack of association in the RRMS and PPMS 
groups reflects the smaller numbers. Furthermore, spinal cord pathology was not assessed, 
which may be of greater clinical relevance in PP than SPMS29; and EDSS scores exceeding 3.5 
essentially reflect impaired mobility and do not capture cognitive or memory impairments,30 
both of which may be associated with cortical pathology.31 Further work using larger 
cohorts and spinal cord examination is needed to explore these issues. 
 
CONCLUSION 
As with SPMS, periventricular and cortical gradients are present in PPMS, and do not appear 
to differ substantially between these subtypes of progressive MS. Histopathological 
examination of the substrates underlying these gradients may provide useful insights into 
the processes leading to them.  
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